Sign Out
Diabetic Patients: In accordance with current clinical practice, some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycaemic medications.
Hypersensitivity Reactions: There have been reports in the post-marketing experience of hypersensitivity reactions, including cases of angioedema. Pregabalin should be discontinued immediately if symptoms of angioedema eg. facial, perioral or upper airway swelling occur.
Pregabalin treatment has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in the elderly population. There have also been post-marketing reports of loss consciousness, confusion and mental impairment. Therefore, Patients should be advised to exercise caution until they are familiar with the potential effects of the medications.
Renal Failure: Cases of renal failure have been reported and in some cases discontinuation of pregabalin did show reversibility of this adverse reaction.
Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Renal impairment, diabetes, discontinue if symptoms of angioedema occurs. CHF. Monitor patients for signs of suicidal ideation & behaviours. May impair ability to drive or operate machinery. Pregnancy & lactation, Adolescent 12-17 yr & children <12 yr. Elderly >65 yr.
Use in Pregnancy: There are no adequate data on the use of pregabalin in pregnant women, Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown. Pregabalin should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the fetus). Effective contraception must be used in women of childbearing potential.
Use in Lactation: It is known if pregabalin is excreted in the breast milk of humans; however, it is present in the milk of rats. Therefore, breastfeeding is not recommended during treatment with pregabalin.
